Frank L. Meyskens, Jr.

Professor of Medicine, Biological Chemistry and Public Health, College of Health Sciences
School of Medicine

Director, Chao Family Comprehensive Cancer Center, University of California Irvine

M.D., University of California, San Francisco, 1972

Phone: (714) 456-6310
Fax: (714) 456-2240

University of California, Irvine
Bldg 23 - Rt 81
101 The City Drive
Mail Code: 2675
Orange, CA 92868

picture of Frank L. Meyskens, Jr.

Melanoma, chemoprevention, polyamines.
We are studying the basis of drug resistance of melanoma cells with a particular interest in Ref-1/APE and redox regulation. We have also proposed an alternative model for the etiology and progression of cutaneous melanoma based on the altered redox metabolism in human melanoma cells and developed new anticancer therapies based on these observations.

We are heavily involved in Phase I, II, and III clinical chemoprevention trials involving oral, colon, pancreas cancer, and melanoma and study such compounds as difluromethiornithine, Bowman-Birk Inhibitors (a Soybean-derived compound) SAMe, and Lovastatin.
Publications Research and Symposium:

Gerner E.W., Meyskens F.L., Jr. Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation. Clin Cancer Res. 2009 Feb 1;15(3):758-61. Review

McEligot, A.J., Yang, S., Meyskens, F.L., Jr. Redox regulation by intrinsic species and extrinsic nutrients in normal and cancer cells. Annu. Rev. Nutr. 25:261-95, 2005
  Peer Review:

Yang, Z., Yang, S., Minser, B.J., Chiu, R., Liu, F., Meyskens, F.L., Jr. Nitric oxide initiates progression of human melanoma via a feedback loop medited by apurinic/apyrimidinic endonuclease-1/redox factor-1, which is inhibited by resveratrol. Mol Cancer Ther. 2008 Dec;7(12):3751-60.

Meyskens, F.L., Jr., McLaren, C.E., Pelot, D., Fujikawa-Brooks, S., Carpenter, P., Hawk, E., Kelloff, G., Lawson, M.J., Kidao, J., McCracken, J., Albers, C.G., Ahnan, D.J., Turgeon, D.K., Goldschmid, S., Lanoe, P., Hagedorn, C.H., Gillan, D.L., Gerner, E.W.: Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A randomized placebo-controlled, Double-Blind Trial. Cancer Prev Res June 1:15-32, 2008

Meyskens, F.L., Jr., Berwick, M. UV or not UV?: Metals, the Answer. Cancer Epi. Biom. Prev. 2008, Feb 17:268-270.

Meyskens, F.L., Jr., Ransohoff, D.F. Predicting Risk for the Appearance of Melanoma. Journal of Clinical Oncology 24: 3522-3533, 2006.
Graduate Programs Cancer Biology

Research Center Cancer Center
Link to this profile
Last updated 04/20/2010